Puma Biotechnology (PBYI) EBITDA (2010 - 2026)
Puma Biotechnology's (PBYI) quarterly EBITDA came in at -$3.8 million in Q1 2026, down 196.08% YoY from $4.0 million in Q1 2025, and down 122.38% on a QoQ basis from $17.1 million in Q4 2025.
Puma Biotechnology (PBYI) EBITDA (2010 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 17 years of EBITDA data on file, last reported at -$3.8 million in Q1 2026.
- Quarterly EBITDA fell 196.08% year-over-year to -$3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.5 million (down 20.84% YoY) and the FY2025 annual result came in at $37.3 million, up 20.45% from the prior year.
- EBITDA retreated to -$3.8 million in Q1 2026, from $17.1 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of $22.1 million in Q3 2024 to a low of -$3.8 million in Q1 2026.
- A 5-year average of $7.1 million and a median of $6.6 million in 2025 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2023 — EBITDA surged 684.34% — and 2026, when it tumbled 196.08%.
- Tracing PBYI's EBITDA over 5 years: stood at $10.0 million in 2022, then soared by 47.74% to $14.8 million in 2023, then decreased by 9.68% to $13.4 million in 2024, then climbed by 27.99% to $17.1 million in 2025, then sank by 122.38% to -$3.8 million in 2026.
- The last three EBITDA figures came in at -$3.8 million (Q1 2026), $17.1 million (Q4 2025), and $9.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 7.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.59 Mn |
| Mar 31, 2026 | -3.83 Mn |
| Dec 31, 2025 | 17.11 Mn |
| Sep 30, 2025 | 9.57 Mn |
| Jun 30, 2025 | 6.64 Mn |
| Mar 31, 2025 | 3.98 Mn |
| Dec 31, 2024 | 13.37 Mn |
| Sep 30, 2024 | 22.08 Mn |
| Jun 30, 2024 | -2.18 Mn |
| Mar 31, 2024 | -2.30 Mn |
| Dec 31, 2023 | 14.80 Mn |
| Sep 30, 2023 | 8.59 Mn |
| Jun 30, 2023 | 4.89 Mn |
| Mar 31, 2023 | 4.37 Mn |
| Dec 31, 2022 | 10.02 Mn |
| Sep 30, 2022 | 2.39 Mn |
| Jun 30, 2022 | 12.06 Mn |
| Mar 31, 2022 | -747,000.00 |
| Dec 31, 2021 | 6.83 Mn |
| Sep 30, 2021 | -8.95 Mn |